Newsroom

New research published online May 20 by the New England Journal of Medicine and co-led by Temple’s Gerard J. Criner, MD, FACP, FACCP shows that the asthma drug benralizumab failed to decrease annual COPD exacerbation rates for patients with moderate to very severe COPD.

The U.S. Food and Drug Administration (FDA) has granted premarket notification clearance for two catheters invented by Riyaz Bashir, MD, FACC, RVT and Nicholas Green. Thrombolex is a company founded in partnership with Temple University to develop these catheter-based clot dissolving devices.

A trio of students from the Lewis Katz School of Medicine at Temple University described the profound impact that receiving scholarships for their medical studies has had on their lives.